dc.contributor.author
You, Yu
dc.contributor.author
Kheimar, Ahmed M.
dc.contributor.author
Vychodil, Tereza
dc.contributor.author
Kossak, Lisa
dc.contributor.author
Sabsabi, Mohammad A.
dc.contributor.author
Conradie, Andelé M.
dc.contributor.author
Reddy, Sanjay M.
dc.contributor.author
Bertzbach, Luca D.
dc.contributor.author
Kaufer, Benedikt B.
dc.date.accessioned
2024-09-03T11:24:32Z
dc.date.available
2024-09-03T11:24:32Z
dc.identifier.uri
https://refubium.fu-berlin.de/handle/fub188/44773
dc.identifier.uri
http://dx.doi.org/10.17169/refubium-44484
dc.description.abstract
Marek’s disease virus (MDV) integrates its genome into the telomeres of host chromosomes and causes fatal lymphomas in chickens. This integration is facilitated by telomeric repeat sequences (TMRs) at the ends of the viral genome, and is crucial for MDV-induced lymphomagenesis. The SB-1 vaccine virus is commonly used in commercial bivalent vaccines against MDV and also contains TMRs at its ends. Here, we demonstrate that SB-1 efficiently integrates its genome into the chromosomes of latently infected T cells. Deletion of the TMRs from the SB-1 genome did not affect virus replication, but severely impaired virus integration and genome maintenance in latently infected T cells and in chickens. Strikingly, the reduced integration and maintenance of latent SB-1 significantly impaired vaccine protection. Taken together, our data revealed that the TMRs facilitate SB-1 integration and that integration and/or maintenance of the latent viral genome is critical for vaccine protection.
en
dc.format.extent
8 Seiten
dc.rights.uri
https://creativecommons.org/licenses/by/4.0/
dc.subject
Herpes virus
en
dc.subject
Tumour virus infections
en
dc.subject
Marek’s disease virus
en
dc.subject.ddc
500 Naturwissenschaften und Mathematik::570 Biowissenschaften; Biologie::570 Biowissenschaften; Biologie
dc.title
Telomeric repeats in the commercial SB-1 vaccine facilitate viral integration and contribute to vaccine efficacy
dc.type
Wissenschaftlicher Artikel
dcterms.bibliographicCitation.articlenumber
154
dcterms.bibliographicCitation.doi
10.1038/s41541-024-00945-6
dcterms.bibliographicCitation.journaltitle
npj Vaccines
dcterms.bibliographicCitation.volume
9
dcterms.bibliographicCitation.url
https://doi.org/10.1038/s41541-024-00945-6
refubium.affiliation
Veterinärmedizin
refubium.affiliation.other
Institut für Virologie
refubium.funding
Springer Nature DEAL
refubium.note.author
Die Publikation wurde aus Open Access Publikationsgeldern der Freien Universität Berlin gefördert.
refubium.resourceType.isindependentpub
no
dcterms.accessRights.openaire
open access
dcterms.isPartOf.eissn
2059-0105